Mitoxantrone clinical trials
Mitoxantrone is named as an intervention in 13 current clinical trials in our Canada, Australia, Israel, China, Germany, Netherlands, Mexico, Ireland, France, Switzerland, Italy, Poland, Czechia, Turkey, Japan and South Korea registers. 4 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Children's Oncology Group (3). The most-studied condition is Acute Myeloid Leukemia.
Where Mitoxantrone is approved
All regulators →Of the three regulators tracked here, the first to approve Mitoxantrone was the US, on 23 Dec 1987.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
How Mitoxantrone works
All drug targets →- DNA topoisomerase II alpha inhibitor InhibitorTarget: TOP2A DNA topoisomerase II alpha✓ In ChEMBL and the Guide to Pharmacology
- T-cell non-Hodgkin lymphomaPhase 3
- Acute lymphoblastic leukemiaPhase 3
- Acute myeloid leukemiaPhase 3
- Acute myeloid leukemia by FAB classificationPhase 3
- Breast cancerPhase 3
- Chronic myeloid leukemiaPhase 3
- Diffuse large B-cell lymphomaPhase 3
- Follicular lymphomaPhase 3
- Lymphoblastic lymphomaPhase 3
- Lymphoplasmacytic lymphomaPhase 3
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL58, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 7242, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Mitoxantrone
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Mitoxantrone
- ATC code
- L01DB07
- ChEMBL
- CHEMBL58
- DrugBank
- DB01204
- PubChem CID
- 4212
- CAS number
- 65271-80-9
- FDA UNII
- BZ114NVM5P
- Wikidata
- Q239426
- Wikipedia
- Mitoxantrone
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Mitoxantrone
13 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Mitoxantrone
19 conditionsAll 19 conditions
| Condition (as registered) | Trials |
|---|---|
| Acute Myeloid Leukemia | 2 |
| Acute Myeloid Leukaemia | 1 |
| AML, Adult | 1 |
| FLT3-mutated Acute Myeloid Leukemia | 1 |
| Newly Diagnosed Acute Myeloid Leukemia (AML) | 1 |
| Untreated AML | 1 |
| AML Arising From Myelodysplastic Syndrome (MDS) | 1 |
| AML Arising From Antecedent Hematologic Disorder (AHD) | 1 |
| Acute Myeloid Leukemia in Children | 1 |
| Recurrent B Acute Lymphoblastic Leukemia | 1 |
| Lymphoblastic Leukemia | 1 |
| Acute Lymphoblastic Leukemia | 1 |
| Papillary Thyroid Cancer | 1 |
| Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA | 1 |
| Down Syndrome | 1 |
| Myelodysplastic Syndrome | 1 |
| Myeloid Leukemia Associated With Down Syndrome | 1 |
| Recurrent Acute Myeloid Leukemia | 1 |
| Refractory Acute Myeloid Leukemia | 1 |
Sponsors
lead sponsor per trialBy country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Mitoxantrone trials
How many clinical trials are testing Mitoxantrone?
13 current trials in our Canada, Australia, Israel, China, Germany, Netherlands, Mexico, Ireland, France, Switzerland, Italy, Poland, Czechia, Turkey, Japan and South Korea registers name Mitoxantrone (also registered as CL 232315) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Mitoxantrone trials recruiting patients?
Yes. 4 of the 13 trials are recruiting: 2 with sites in Canada, 1 with sites in Australia, 1 with sites in Israel, 1 with sites in China, 1 with sites in Netherlands and 1 with sites in Mexico. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Mitoxantrone clinical trials?
Children's Oncology Group (3), National Cancer Institute (NCI) (2), University of Birmingham (1) and Institute of Hematology & Blood Diseases Hospital, China (1), among 10 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Are there Mitoxantrone clinical trials in Ireland?
Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Mitoxantrone works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Mitoxantrone works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Mitoxantrone (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.